Neurocrine Biosciences, Inc (NASDAQ: NBIX) kicked off on Tuesday, down -0.34% from the previous trading day, before settling in for the closing price of $136.99. Over the past 52 weeks, NBIX has traded in a range of $110.95-$157.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.77%. While this was happening, its average annual earnings per share was recorded 68.22%. With a float of $98.54 million, this company’s outstanding shares have now reached $101.20 million.
Considering the fact that the conglomerate employs 1400 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.0%, operating margin of 26.19%, and the pretax margin is 23.26%.
Neurocrine Biosciences, Inc (NBIX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Neurocrine Biosciences, Inc is 2.68%, while institutional ownership is 91.86%. The most recent insider transaction that took place on Dec 17 ’24, was worth 147,285. In this transaction Chief Regulatory Officer of this company sold 1,091 shares at a rate of $135.00, taking the stock ownership to the 2,507 shares. Before that another transaction happened on Dec 17 ’24, when Company’s Officer proposed sale 1,091 for $133.05, making the entire transaction worth $145,158.
Neurocrine Biosciences, Inc (NBIX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
Take a look at Neurocrine Biosciences, Inc’s (NBIX) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.16. Likewise, its price to free cash flow for the trailing twelve months is 31.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.73, a number that is poised to hit 1.57 in the next quarter and is forecasted to reach 6.32 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
Compared to the last year’s volume of 0.88 million, its volume of 1.41 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 74.38%. Additionally, its Average True Range was 3.32.
During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 58.25%, which indicates a significant decrease from 75.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.15% in the past 14 days, which was lower than the 42.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $124.60, while its 200-day Moving Average is $132.99. Nevertheless, the first resistance level for the watch stands at $137.82 in the near term. At $139.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $140.10. If the price goes on to break the first support level at $135.54, it is likely to go to the next support level at $134.55. Now, if the price goes above the second support level, the third support stands at $133.26.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats
The company with the Market Capitalisation of 13.82 billion has total of 101,247K Shares Outstanding. Its annual sales at the moment are 1,887 M in contrast with the sum of 249,700 K annual income. Company’s last quarter sales were recorded 622,100 K and last quarter income was 129,800 K.
